A patient came to DiFrancesco Plastic Surgery last year for a lower body lift after losing ninety pounds. She was a good candidate on paper: stable weight for eleven months, a non-smoker, with reasonable expectations. Her preoperative labs came back with a TSH of 8.4 and a free T4 at the bottom of the range. She had never been told she was hypothyroid. She had attributed her fatigue, cold hands, and stubborn last fifteen pounds to the weight loss itself.

DiFrancesco Plastic Surgery treated the thyroid first and operated four months later. There is no way to prove her result was better than it would have been otherwise. But she recovered like a patient whose physiology was working with her instead of against her, and Dr. DiFrancesco would not want to make a long incision through the abdominal wall of a patient with untreated hypothyroidism when there is an option to correct it first.

That case is why hormone health is such a central part of how DiFrancesco Plastic Surgery approaches body contouring.

Why a Plastic Surgery Practice Focuses on Hormone Health

Surgery is a metabolic event. It is often described in mechanical terms: tissue is excised, planes are dissected, edges are approximated. But what determines the outcome is what the body does afterward. Collagen deposition, capillary ingrowth, immune signaling, protein synthesis, and fluid handling all run on an endocrine substrate.

For most of plastic surgery’s history, aesthetic surgery and hormone management lived in separate buildings, usually with a gynecologist or an endocrinologist handling one and a surgeon handling the other, with little communication between them. The post-weight-loss patient population broke that separation open, because rapid weight loss is itself an endocrine event. It changes sex hormone binding globulin. It shifts estrogen out of adipose tissue in women. It frequently unmasks thyroid disease. In men who lose a large amount of visceral fat, it can raise total testosterone substantially without a single prescription.

A body cannot be contoured well without understanding the metabolic state that produced it.

Cortisol and Surgical Healing

Every operation triggers a cortisol surge, and that is not a complication, it is the point. Cortisol mobilizes glucose, maintains vascular tone, and modulates the inflammatory cascade during the hours when the body is most vulnerable. A patient who cannot mount that response is a patient in trouble.

The problem is the patient who arrives already elevated. Chronic stress, poor sleep, untreated obstructive sleep apnea, alcohol, and aggressive caloric restriction all raise baseline cortisol. Sustained elevation does the opposite of what the acute surge does: it suppresses fibroblast proliferation, thins the dermis, impairs collagen cross-linking, blunts the immune response to bacterial contamination, and drives visceral fat deposition. Patients on long-term systemic corticosteroids for asthma or autoimmune disease fall into the same category and need to be identified before the day of surgery, not on it.

One point worth being direct about, because it is where a lot of wellness marketing goes off the rails: “adrenal fatigue” is not a diagnosis. There is no credible evidence for the idea of adrenal glands that get tired and stop producing cortisol from chronic stress, and endocrine societies have repeatedly reviewed the claim and rejected it. Real adrenal insufficiency exists, it is diagnosed with a morning cortisol test and an ACTH stimulation test, and it is dangerous. A four-point salivary cortisol curve sold with a supplement bundle is not that.

What matters practically for surgical planning: sleep quality, alcohol intake, whether a patient is trying to lose another twenty pounds in the eight weeks before an operation, and whether anyone has screened them for sleep apnea. Those are the factors that actually move cortisol in the perioperative window.

Thyroid Function and Wound Healing

Thyroid hormone regulates basal metabolic rate, protein synthesis, and fibroblast activity. Hypothyroidism is associated with delayed wound healing, reduced tensile strength in healing tissue, tissue edema, bradycardia, altered drug clearance, and impaired thermoregulation on the operating table. Overt hypothyroidism is a reason to delay elective surgery and correct it first. That is not controversial and it is not new.

What is genuinely debated is subclinical hypothyroidism, meaning elevated TSH with normal free T4. The surgical literature does not support treating every patient with a TSH of 5.2 before an elective procedure, and DiFrancesco Plastic Surgery does not either. But a TSH drawn as part of a preoperative panel is one of the highest-yield tests in aesthetic surgery, for a simple reason: thyroid disease is common, disproportionately affects women in the demographic that seeks body contouring, and produces symptoms, including fatigue, weight resistance, hair thinning, dry skin, and cold intolerance, that patients and physicians both routinely misattribute to aging, menopause, or the weight loss itself.

The panel used at DiFrancesco Plastic Surgery is TSH, free T4, free T3, and TPO antibodies. The antibodies matter because Hashimoto’s is the most common cause of hypothyroidism in this country, and knowing a patient is antibody-positive with a normal TSH shows where she is likely headed over the next decade.

One caution that comes up constantly in the post-GLP-1 population: rapid weight loss lowers T3 as an adaptive response. That is physiology, not disease, and it usually should not be treated with thyroid hormone. Chasing a low T3 with liothyronine in a patient who is simply in a caloric deficit is how people end up iatrogenically hyperthyroid.

Testosterone: Not Only a Men’s Issue, and Not a Free Lunch

In men, low testosterone is associated with reduced lean mass, increased visceral adiposity, poor exercise tolerance, low mood, and low motivation, the exact profile that undermines the long-term result of gynecomastia correction or male body contouring. A patient whose body composition is drifting in the wrong direction will not hold a surgical result, no matter how clean the operation was.

February 2025 changed the conversation meaningfully. Following the TRAVERSE trial, which found testosterone replacement noninferior to placebo for major adverse cardiac events in hypogonadal men at elevated cardiovascular risk, the FDA removed the boxed warning language about increased cardiovascular risk from all testosterone products.

But the same labeling action added something new: a class-wide warning about increased blood pressure, based on ambulatory monitoring studies. The “limitation of use” language for age-related hypogonadism was retained. So the honest reading is not that testosterone is now safe across the board. It is that the cardiovascular fear was overstated, blood pressure needs to be monitored, and testosterone remains a treatment for diagnosed hypogonadism rather than a wellness accessory.

Testosterone in women deserves a clear-eyed accounting. There is no FDA-approved testosterone product for women in the United States at any dose, so every prescription written for a woman is off-label or compounded. The 2019 global consensus position statement endorses one indication with randomized evidence behind it, hypoactive sexual desire disorder in postmenopausal women, and is emphatic on one point that DiFrancesco Plastic Surgery agrees with completely: the target is premenopausal physiologic concentration, not above it.

Where DiFrancesco Plastic Surgery differs from the strictest reading of that statement is in treating symptomatic women outside the HSDD indication. That treatment happens with full awareness that the trial evidence for energy, mood, and body composition in women is thinner than the marketing implies. What makes that approach defensible is not enthusiasm. It is the dosing target and the monitoring, which is the same standard that separates responsible practice from the alternative regardless of what route is used.

Pellets generate the most questions, and the criticism aimed at them in the literature is often aimed at the wrong target. The documented adverse effects, including acne, scalp hair loss with hair growth elsewhere, voice change, and clitoromegaly, are dose effects. They come from supraphysiologic levels. They are not intrinsic to the delivery route.

DiFrancesco Plastic Surgery uses subcutaneous pellets, dosed to physiologic concentrations, for pharmacokinetic reasons. Pellets release steadily rather than in a spike. A weekly injection produces a peak in the first day or two and a trough by day six or seven, and patients feel both ends of that curve. Daily gels solve the peak-and-trough problem but introduce transference risk to a partner or a child and depend on perfect adherence to a daily application most people eventually get careless about. A pellet delivers a flat curve and removes adherence from the equation entirely.

In this practice, the release interval runs about fourteen weeks in women and about eighteen weeks in men. That timing is what makes the approach workable: it means three to four office visits a year in women, two to three in men, each of which is a natural checkpoint to re-draw levels and adjust the next dose rather than a refill sent without a conversation.

The discipline the route demands is real and worth naming directly. A pellet cannot be withdrawn once it is placed, so the dose has to be right going in, which means dosing conservatively, re-checking levels at steady state, and titrating on the next insertion rather than the current one. Done that way, testosterone pellets are a controlled, monitored therapy. Done as a volume business with a standard dose for every patient and no follow-up labs, they are how women end up with an irreversible voice change. The problem has never been the pellet. It is the absence of a physician measuring anything.

Estrogen: Skin, Collagen, and the Perioperative Clotting Question

Estrogen receptors are present in dermal fibroblasts and keratinocytes. Estrogen influences dermal collagen content, skin thickness, hydration, and elasticity. The frequently cited figure from the dermatologic literature is that women lose roughly 30% of skin collagen in the first five years after menopause, then about 2% per year thereafter. Even if that number is imprecise, the direction is not in question, and it maps onto what is seen clinically: the acceleration in facial and body skin laxity in the years around menopause is not gradual.

November 10, 2025 was another regulatory turning point. HHS and the FDA initiated removal of the boxed warnings related to cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, reversing labeling that had been in place since 2003 and that dramatically suppressed use for two decades. The reasoning was that the Women’s Health Initiative population averaged 63 years of age, used conjugated equine estrogens with medroxyprogesterone, and does not represent a 52-year-old starting transdermal estradiol within a few years of her final period.

Two things are worth keeping straight. The endometrial cancer warning was not removed for systemic estrogen-alone products. And information about cardiovascular and breast cancer risk remains in the labeling; it moved out of the box, it did not disappear. A label change is a correction of overstatement, not an all-clear.

Where estrogen genuinely intersects with surgery is clotting. Oral estrogen undergoes first-pass hepatic metabolism and increases production of clotting factors; it is associated with roughly double the perioperative VTE risk. Transdermal estradiol largely bypasses that mechanism and carries substantially lower thrombotic risk. That difference drives the management approach at DiFrancesco Plastic Surgery:

Oral estrogen for major body contouring is typically held two to four weeks preoperatively, or converted to transdermal in advance.

Transdermal estradiol is frequently continued, depending on Caprini score, personal or family VTE history, and length of the operation.

Vaginal estrogen has minimal systemic absorption, and it is not routinely stopped.

None of that is a fixed rule. It is a risk calculation that includes the cost of stopping. The plastic surgery literature on facial feminization has made this point well: patients who discontinue hormone therapy for surgery frequently find it a difficult experience, and at least one series found no VTE events across nearly 300 procedures. Abrupt withdrawal of estrogen in a menopausal woman four weeks before an operation returns her hot flashes, wrecks her sleep, and destabilizes her mood at precisely the moment she needs sleep and stability. That has a cost, and it belongs in the conversation.

Progesterone: The Hormone That Gets Forgotten

Progesterone tends to be treated as an afterthought, the hormone added to protect the endometrium. Endometrial protection is essential and non-negotiable for any woman with a uterus on systemic estrogen. But progesterone does more that matters perioperatively.

Micronized progesterone is metabolized to allopregnanolone, a positive allosteric modulator at the GABA-A receptor, which is why oral micronized progesterone dosed at night improves sleep quality in many women. Sleep is not a soft variable in recovery. It is when growth hormone pulses, when tissue repair is most active, and when pain tolerance is restored. A patient sleeping four broken hours a night through her first postoperative month heals worse and reports more pain than one sleeping seven.

It is worth distinguishing that micronized progesterone and synthetic progestins are not interchangeable. Much of the breast cancer signal in the WHI came from the estrogen-plus-medroxyprogesterone arm. Observational European data suggest micronized progesterone may carry a more favorable profile, though the evidence is not at the level of a randomized trial and should not be presented as if it were.

The Baseline Lab Panel DiFrancesco Plastic Surgery Uses

For patients considering body contouring, hormone therapy, or both, the baseline panel includes:

Metabolic and thyroid: CBC, CMP, HbA1c, fasting insulin, lipid panel, TSH, free T4, free T3, TPO antibodies

Sex hormones: total and free testosterone, SHBG, estradiol, progesterone (timed to cycle in premenopausal patients), FSH, LH, DHEA-S

Adrenal: morning cortisol, with ACTH stimulation testing only if there is a clinical reason

Nutritional and healing: ferritin, vitamin D, B12, albumin and prealbumin, the last two of which matter enormously after bariatric surgery or sustained GLP-1 use

Timing matters as much as the panel itself. Labs are best drawn eight to twelve weeks before an elective operation. That is enough runway to correct a thyroid deficit, replete iron or vitamin D, adjust an estrogen route from oral to transdermal, or discover that a patient’s protein intake has been thirty grams a day for a year.

What Hormone Optimization Is Not

Hormone optimization is not a lab value chased to the top of a reference range because higher sounds better. It is not a treatment applied without a diagnosis. It is not a subscription. And it is not a substitute for the things that actually determine surgical outcomes: not smoking, adequate protein, weight stability, controlled blood sugar, and a realistic operation performed well.

Hormone management became a built-in part of this practice because the alternative was watching good surgical results erode over three years in patients whose underlying physiology no one was managing. Surgery removes tissue. It does not change the metabolic environment that the remaining tissue lives in.

Both problems are worth solving. They are different problems, and treating one as a substitute for the other has never served a patient well.

Common Questions About Hormone Testing Before Plastic Surgery

Do I need hormone testing before plastic surgery?

Hormone testing is not required for every patient considering plastic surgery, but a baseline panel including TSH, free T4, and a metabolic panel is high-yield for anyone considering major body contouring, particularly after significant weight loss, when thyroid disease and nutritional deficiency are common and frequently undiagnosed.

Do I have to stop hormone replacement therapy before surgery?

Whether a patient needs to stop hormone replacement therapy before surgery depends on the route. Oral estrogen roughly doubles perioperative clot risk and is commonly held two to four weeks before major surgery or switched to transdermal in advance. Transdermal estradiol carries substantially lower risk and is often continued. Vaginal estrogen is usually continued. Testosterone and progesterone are generally lower-risk. This is an individualized decision made between a patient, her surgeon, and her prescriber.

Did the FDA say hormone replacement therapy is safe now?

In November 2025, the FDA initiated removal of the boxed warnings regarding cardiovascular disease, breast cancer, and probable dementia from menopausal hormone therapy products, after concluding the warnings overstated risk for women starting therapy under 60 and within ten years of menopause. Risk information remains in the labeling outside the box, and the endometrial cancer warning was retained for systemic estrogen-alone products.

Can hormone therapy replace a tummy tuck or a body lift?

Hormone therapy cannot replace a tummy tuck or a body lift. Hormone optimization can improve body composition, skin quality, energy, and the durability of a surgical result, but it cannot remove redundant skin or repair a separated abdominal wall. Those are mechanical problems that require a mechanical solution.

Is testosterone appropriate for women?

No testosterone product is FDA-approved for women in the United States, so all use is off-label or compounded. The indication with randomized evidence behind it is hypoactive sexual desire disorder in postmenopausal women. In practice, DiFrancesco Plastic Surgery treats symptomatic women more broadly than that, always dosed to premenopausal physiologic concentrations rather than above them, with levels re-checked at steady state.

How long do hormone pellets last? 

At DiFrancesco Plastic Surgery, hormone pellets last roughly fourteen weeks in women and eighteen weeks in men. Pellets release steadily over that interval rather than producing the peak-and-trough pattern of injections, and they eliminate both the daily-adherence burden and the transference risk that come with topical gels. The interval also builds in a natural schedule for repeat lab work before the next insertion.

Are testosterone pellets safe?

The adverse effects associated with testosterone pellets, including acne, scalp hair thinning, and voice change, are effects of supraphysiologic dosing, not of the delivery route itself. Because a pellet cannot be removed once placed, the dose must be conservative going in, levels re-checked at steady state, and adjustments made at the next insertion. Pellets prescribed at a standard dose without follow-up laboratory monitoring are where problems occur.

What is “adrenal fatigue”?

“Adrenal fatigue” is not a recognized medical diagnosis and is not supported by evidence. Adrenal insufficiency is a real and serious condition diagnosed with a morning cortisol test and ACTH stimulation testing. Fatigue is far more often explained by thyroid disease, iron deficiency, sleep apnea, depression, or inadequate caloric and protein intake.

---